AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
AS-924 is an oral prodrug of the antibiotic ceftizoxime (CTIZ), a parenteral use cephalosporin. This novel prodrug, produced by esterifying CTIZ with a lipophilic pivaloyloxymethyl (POM) group and introducing a water soluble L-alanyl group, is expected to increase the bioavailability and thereby, augment the antibacterial activity of CTIZ in vivo compared with existing prodrugs. To study the effect of the L-alanyl group in AS-924 on its bioavailability, the plasma concentration profiles of CTIZ in dogs were examined following the dosing of AS-924 and CTIZ-POM, in powder form, after pretreatment with the antacid ranitidine, and following the dosing of AS-924 after pretreatment with a gastrointestinal motility stimulant metoclopramide or suppressant scopolamine butylbromide. The absorption rate of AS-924 was constant under these different conditions due to its unique balance of lipophilicity and water solubility. CTIZ is as antibacterially active as pre-existing oral cephalosporins against Gram-positive clinical isolates, while being more active against all Gram-negative isolates-particularly Enterobacteriaceae and Haemophilus influenzae. A simulation model for the eradication profile of bacteria in computer programmed pharmacokinetic (PK) system was carried out to study the antibacterial action of CTIZ in human. CTIZ was proven to eradicate Streptococcus pneumoniae and H. influenzae effectively, while cefpodoxime (CPOD), the active moiety of CPOD proxetil, eradicated S. pneumoniae, but not H. influenzae. These results confirm that, AS-924 is a potent oral antibiotic and would be expected to be clinically effective and efficient.
Mori
N
N
Institute for Life Science Research, Asahi Kasei Corporation, 632-1 Mifuku Ohito cho, Tagata-gun, 410-2321, Shizuoka, Japan. mori.nb@om.asahi-kasei.co.jp
Kodama
T
T
Sakai
A
A
Suzuki
T
T
Sugihara
T
T
Yamaguchi
S
S
Nishijima
T
T
Aoki
A
A
Toriya
M
M
Kasai
M
M
Hatano
S
S
Kitagawa
M
M
Yoshimi
A
A
Nishimura
K
K
D000284:Administration, Oral; D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D001682:Biological Availability; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003198:Computer Simulation; D004285:Dogs; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D008954:Models, Biological; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits
D002511:Cephalosporins; D011355:Prodrugs; C121334:ceftizoxime alapivoxil; D015296:Ceftizoxime